Discovery of a New Siderophore Cephalosporin, Cefiderocol
Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gra...
Gespeichert in:
| Veröffentlicht in: | YAKUGAKU ZASSHI 2024/06/01, Vol.144(6), pp.627-631 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 631 |
|---|---|
| container_issue | 6 |
| container_start_page | 627 |
| container_title | YAKUGAKU ZASSHI |
| container_volume | 144 |
| creator | Yamano, Yoshinori |
| description | Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens. |
| doi_str_mv | 10.1248/yakushi.23-00197-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3064142334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3064142334</sourcerecordid><originalsourceid>FETCH-LOGICAL-c251t-743ce38fe5a33e0c7575a6d24a4871231ad33c16db5fa2cfe87da47e5c84c6f73</originalsourceid><addsrcrecordid>eNpFkE1PwzAMhiMEYtPYH-CAeuRARxKnTXZE41sIDsA5ylKXFrqlJC1o_56wjeGDLcuPX1svIceMThgX6nxlPvpQ1RMOKaVsKlO2R4YMhEwzDmyfDCkFluZTCgMyDqGeU8pjZEwdkgEoxTMh2ZBML-tg3Rf6VeLKxCSP-J081wV611bOYzLDtjKNC63z9fIstuV6aF1zRA5K0wQcb-uIvF5fvcxu04enm7vZxUNq47EulQIsgioxMwBIrcxkZvKCCyOUZPFVUwBYlhfzrDTclqhkYYTEzCph81LCiJxudFvvPnsMnV7El7FpzBJdHzTQXDDBAURE-Qa13oXgsdStrxfGrzSj-tc1vXVNc9Br1zSLSydb_X6-wGK38udRBO43wHvozBvuAOO72ja402RC6Hyd_9V3kK2M17iEH1X5g9s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3064142334</pqid></control><display><type>article</type><title>Discovery of a New Siderophore Cephalosporin, Cefiderocol</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>J-STAGE</source><creator>Yamano, Yoshinori</creator><creatorcontrib>Yamano, Yoshinori</creatorcontrib><description>Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens.</description><identifier>ISSN: 0031-6903</identifier><identifier>ISSN: 1347-5231</identifier><identifier>EISSN: 1347-5231</identifier><identifier>DOI: 10.1248/yakushi.23-00197-1</identifier><identifier>PMID: 38825471</identifier><language>jpn</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Acinetobacter baumannii ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; carbapenem-resistant ; Carbapenems - pharmacology ; Cefiderocol ; Cephalosporins - chemistry ; Cephalosporins - pharmacology ; Drug Discovery ; Drug Resistance, Bacterial ; Enterobacterales ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacterial Infections - drug therapy ; Humans ; Iron - metabolism ; Iron Chelating Agents - pharmacology ; iron transporter ; Pseudomonas aeruginosa ; siderophore ; Siderophores - chemistry</subject><ispartof>YAKUGAKU ZASSHI, 2024/06/01, Vol.144(6), pp.627-631</ispartof><rights>2024 The Pharmaceutical Society of Japan</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c251t-743ce38fe5a33e0c7575a6d24a4871231ad33c16db5fa2cfe87da47e5c84c6f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38825471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamano, Yoshinori</creatorcontrib><title>Discovery of a New Siderophore Cephalosporin, Cefiderocol</title><title>YAKUGAKU ZASSHI</title><addtitle>YAKUGAKU ZASSHI</addtitle><description>Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens.</description><subject>Acinetobacter baumannii</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>carbapenem-resistant</subject><subject>Carbapenems - pharmacology</subject><subject>Cefiderocol</subject><subject>Cephalosporins - chemistry</subject><subject>Cephalosporins - pharmacology</subject><subject>Drug Discovery</subject><subject>Drug Resistance, Bacterial</subject><subject>Enterobacterales</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Humans</subject><subject>Iron - metabolism</subject><subject>Iron Chelating Agents - pharmacology</subject><subject>iron transporter</subject><subject>Pseudomonas aeruginosa</subject><subject>siderophore</subject><subject>Siderophores - chemistry</subject><issn>0031-6903</issn><issn>1347-5231</issn><issn>1347-5231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1PwzAMhiMEYtPYH-CAeuRARxKnTXZE41sIDsA5ylKXFrqlJC1o_56wjeGDLcuPX1svIceMThgX6nxlPvpQ1RMOKaVsKlO2R4YMhEwzDmyfDCkFluZTCgMyDqGeU8pjZEwdkgEoxTMh2ZBML-tg3Rf6VeLKxCSP-J081wV611bOYzLDtjKNC63z9fIstuV6aF1zRA5K0wQcb-uIvF5fvcxu04enm7vZxUNq47EulQIsgioxMwBIrcxkZvKCCyOUZPFVUwBYlhfzrDTclqhkYYTEzCph81LCiJxudFvvPnsMnV7El7FpzBJdHzTQXDDBAURE-Qa13oXgsdStrxfGrzSj-tc1vXVNc9Br1zSLSydb_X6-wGK38udRBO43wHvozBvuAOO72ja402RC6Hyd_9V3kK2M17iEH1X5g9s</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Yamano, Yoshinori</creator><general>The Pharmaceutical Society of Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240101</creationdate><title>Discovery of a New Siderophore Cephalosporin, Cefiderocol</title><author>Yamano, Yoshinori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c251t-743ce38fe5a33e0c7575a6d24a4871231ad33c16db5fa2cfe87da47e5c84c6f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2024</creationdate><topic>Acinetobacter baumannii</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>carbapenem-resistant</topic><topic>Carbapenems - pharmacology</topic><topic>Cefiderocol</topic><topic>Cephalosporins - chemistry</topic><topic>Cephalosporins - pharmacology</topic><topic>Drug Discovery</topic><topic>Drug Resistance, Bacterial</topic><topic>Enterobacterales</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Humans</topic><topic>Iron - metabolism</topic><topic>Iron Chelating Agents - pharmacology</topic><topic>iron transporter</topic><topic>Pseudomonas aeruginosa</topic><topic>siderophore</topic><topic>Siderophores - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamano, Yoshinori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>YAKUGAKU ZASSHI</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamano, Yoshinori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of a New Siderophore Cephalosporin, Cefiderocol</atitle><jtitle>YAKUGAKU ZASSHI</jtitle><addtitle>YAKUGAKU ZASSHI</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>144</volume><issue>6</issue><spage>627</spage><epage>631</epage><pages>627-631</pages><artnum>23-00197-1</artnum><issn>0031-6903</issn><issn>1347-5231</issn><eissn>1347-5231</eissn><abstract>Cefiderocol is a novel siderophore-conjugated cephalosporin with a catechol residue acting as an iron chelator. Cefiderocol forms a chelating complex with ferric iron and is transported rapidly into bacterial cells through iron-uptake systems. As a result, cefiderocol shows good activity against Gram-negative bacteria, including carbapenem-resistant isolates that are causing significant global health issues. Cefiderocol has been approved for clinical use in the United States and Europe, where it is being used to treat infection caused by carbapenem-resistant Gram-negative pathogens.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>38825471</pmid><doi>10.1248/yakushi.23-00197-1</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6903 |
| ispartof | YAKUGAKU ZASSHI, 2024/06/01, Vol.144(6), pp.627-631 |
| issn | 0031-6903 1347-5231 1347-5231 |
| language | jpn |
| recordid | cdi_proquest_miscellaneous_3064142334 |
| source | MEDLINE; Alma/SFX Local Collection; J-STAGE |
| subjects | Acinetobacter baumannii Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology carbapenem-resistant Carbapenems - pharmacology Cefiderocol Cephalosporins - chemistry Cephalosporins - pharmacology Drug Discovery Drug Resistance, Bacterial Enterobacterales Gram-Negative Bacteria - drug effects Gram-Negative Bacterial Infections - drug therapy Humans Iron - metabolism Iron Chelating Agents - pharmacology iron transporter Pseudomonas aeruginosa siderophore Siderophores - chemistry |
| title | Discovery of a New Siderophore Cephalosporin, Cefiderocol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A54%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20a%20New%20Siderophore%20Cephalosporin,%20Cefiderocol&rft.jtitle=YAKUGAKU%20ZASSHI&rft.au=Yamano,%20Yoshinori&rft.date=2024-01-01&rft.volume=144&rft.issue=6&rft.spage=627&rft.epage=631&rft.pages=627-631&rft.artnum=23-00197-1&rft.issn=0031-6903&rft.eissn=1347-5231&rft_id=info:doi/10.1248/yakushi.23-00197-1&rft_dat=%3Cproquest_cross%3E3064142334%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3064142334&rft_id=info:pmid/38825471&rfr_iscdi=true |